// App-Quantinova.ai

11500 : Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363).

Researchers

Presenter

  • Lillian Mary Smyth

Principal Investigators

  • Jiabin Tang

  • Juber Ahamad A Patel

  • Fanli Meng

  • S Duygu Selcuklu

  • Daoqi You

  • Aliaksandra Samoila

  • Gaia Schiavon

  • Bob T. Li

  • Pedram Razavi

  • Salvatore Piscuoglio

  • Jorge S. Reis-Filho

  • Clifford A. Hudis

  • Jose Baselga

  • David B. Solit

  • Barry S. Taylor

  • David Michael Hyman

  • Michael F. Berger

  • Sarat Chandarlapaty

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The Royal Marsden Hospital, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • AKT Serine

  • Plasma cell-free DNA

Drug/Treatment

  • AZD-5363

Outcome

  • Unknown

Study Design

  • Multicenteric

Phase

  • I

Study Id's

  • NCT01226316

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved